Viridian Therapeutics, Inc.

Healthcare

NASDAQ:VRDN · NASDAQ Capital Market

Market Cap $1.45B Beta 0.90 P/E (TTM) -4.6

$16.35 +1.30%

+$0.21 today

52W Low $13.18High $34.29

Vol 1.24M · Avg 2.84M

EPS (TTM)-$3.53

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+2.96%

Period High

$33.78

Period Low

$13.30

Latest

$16.35

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

ImmunityBio, Inc.

NASDAQ:IBRX

$7.44B

Cogent Biosciences, Inc.

NASDAQ:COGT

$5.66B

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

$3.75B

Structure Therapeutics Inc.

NASDAQ:GPCR

$2.47B

Vera Therapeutics, Inc.

NASDAQ:VERA

$2.46B

Arcus Biosciences, Inc.

NYSE:RCUS

$2.40B

Celldex Therapeutics, Inc.

NASDAQ:CLDX

$2.08B

Ocular Therapeutix, Inc.

NASDAQ:OCUL

$1.96B

Galapagos N.V.

GLPG

$1.84B

uniQure N.V.

NASDAQ:QURE

$1.74B

What is the latest VRDN filing?

The latest filing shown is 8-K dated Jun 3, 2026.

How many recent filings does VRDN have?

Intrinsic Alpha currently shows 20 recent filings for VRDN.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.